Aptinyx Inc   (APTX)
Other Ticker:  
Price: $0.0960 $0.00 3.115%
Day's High: $0.096 Week Perf: 1.05 %
Day's Low: $ 0.09 30 Day Perf: 47.69 %
Volume (M): 231 52 Wk High: $ 0.24
Volume (M$): $ 22 52 Wk Avg: $0.09
Open: $0.09 52 Wk Low: $0.01

 Market Capitalization (Millions $) 7
 Shares Outstanding (Millions) 68
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -66
 Cash Flow (TTM) (Millions $) -56
 Capital Exp. (TTM) (Millions $) 0

Aptinyx Inc
Aptinyx Inc is a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of novel therapies for neurological disorders. The company is engaged in the research and development of advanced therapies with a particular emphasis on the brain's N-methyl-D-aspartate (NMDA) receptor pathway. Aptinyx's drug candidates aim to modulate this pathway to address the underlying causes of various neurological conditions, including chronic pain, cognitive impairment, and movement disorders. The company utilizes its proprietary chemistry platform to develop small molecules that target specific NMDA receptors. Aptinyx's goal is to bring innovative treatments to patients in need, ultimately improving their quality of life.

   Company Address: 909 Davis Street Evanston 60201 IL
   Company Phone Number: 871-0377   Stock Exchange / Ticker: NASDAQ APTX
   APTX is expected to report next financial results on March 29, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Aptinyx Inc

Exploring the Rising Operational Costs of Aptinyx Inc. in Q1 2023 - The Hidden Story Behind the Flux in Pharma Sector Earnings

In the midst of the attention on the larger players in the Major Pharmaceutical Preparations sector, some smaller corporations are also reporting their financial results. One such company is Aptinyx Inc, which recently released its first quarter earnings for 2023. The results showed that the company recorded an operating shortfall of $-20.322 million, which is a significant figure for a company of its size.
Despite this, the shareholders of Aptinyx Inc are not overly anxious about the current productivity levels of the company, as they are expecting the business model to evolve in the near future. However, it should be noted that the company reported a net deficit of $-21.066 million, which is an extension of the net deficit of $-19.827 million recorded in the same period the previous year. This is concerning for the company, as it means that it has not yet been able to turn a profit.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com